PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
176.45 - 178.59
86.62 - 184.48
124.91M / 173.95M (Avg.)
50.81 | 3.50
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
8.43%
Revenue growth similar to AVGO's 8.54%. Walter Schloss would see if both companies share industry tailwinds.
10.14%
Gross profit growth similar to AVGO's 10.89%. Walter Schloss would assume both firms track common industry trends.
14.71%
EBIT growth below 50% of AVGO's 33.49%. Michael Burry would suspect deeper competitive or cost structure issues.
14.71%
Operating income growth under 50% of AVGO's 33.49%. Michael Burry would be concerned about deeper cost or sales issues.
20.85%
Net income growth at 50-75% of AVGO's 32.22%. Martin Whitman would question fundamental disadvantages in expenses or demand.
20.00%
EPS growth at 50-75% of AVGO's 33.33%. Martin Whitman would suspect a lag in operational efficiency or a higher share count.
19.05%
Diluted EPS growth at 50-75% of AVGO's 36.36%. Martin Whitman would question if share issuance or modest net income gains hamper progress.
2.79%
Share count expansion well above AVGO's 0.25%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
1.07%
Slight or no buyback while AVGO is reducing diluted shares. John Neff might consider the competitor’s approach more shareholder-friendly.
21.21%
Dividend growth above 1.5x AVGO's 12.46%. David Dodd would verify if the firm's cash flow is robust enough for these payouts.
57.42%
OCF growth above 1.5x AVGO's 18.30%. David Dodd would confirm a clear edge in underlying cash generation.
59.52%
FCF growth above 1.5x AVGO's 23.20%. David Dodd would verify if the firm’s strategic investments yield superior returns.
155.66%
10Y revenue/share CAGR under 50% of AVGO's 468.39%. Michael Burry would suspect a lasting competitive disadvantage.
152.06%
5Y revenue/share CAGR under 50% of AVGO's 372.60%. Michael Burry would suspect a significant competitive gap or product weakness.
95.23%
3Y revenue/share CAGR similar to AVGO's 89.66%. Walter Schloss would assume both companies experience comparable short-term cycles.
223.58%
10Y OCF/share CAGR under 50% of AVGO's 801.33%. Michael Burry would worry about a persistent underperformance in cash creation.
94.19%
Below 50% of AVGO's 449.38%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
84.97%
3Y OCF/share CAGR under 50% of AVGO's 220.10%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
314.22%
Below 50% of AVGO's 1753.27%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
524.18%
5Y net income/share CAGR above 1.5x AVGO's 141.18%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
358.31%
3Y net income/share CAGR above 1.5x AVGO's 193.29%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
196.87%
Below 50% of AVGO's 1271.06%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
53.67%
Below 50% of AVGO's 408.20%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
32.92%
Below 50% of AVGO's 291.40%. Michael Burry suspects a serious short-term disadvantage in building book value.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
61.66%
Below 50% of AVGO's 219.73%. Michael Burry suspects the firm invests elsewhere or can’t match the competitor’s dividend policy.
-0.84%
Firm’s AR is declining while AVGO shows 1.28%. Joel Greenblatt sees stronger working capital efficiency if sales hold up.
16.94%
Inventory growth well above AVGO's 1.12%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
2.38%
Asset growth well under 50% of AVGO's 8.96%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
5.29%
BV/share growth above 1.5x AVGO's 2.36%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-7.52%
We’re deleveraging while AVGO stands at 29.30%. Joel Greenblatt considers if we gain a balance-sheet advantage for potential downturns.
5.63%
R&D growth drastically higher vs. AVGO's 0.12%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.
2.92%
We expand SG&A while AVGO cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.